124 related articles for article (PubMed ID: 20934265)
1. "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I).
Glynne-Jones R; Sebag-Montefiore D; Adams R; McDonald A; Gollins S; James R; Northover JM; Meadows HM; Jitlal M;
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1488-94. PubMed ID: 20934265
[TBL] [Abstract][Full Text] [Related]
2. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Lancet; 1996 Oct; 348(9034):1049-54. PubMed ID: 8874455
[TBL] [Abstract][Full Text] [Related]
3. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).
Rivin Del Campo E; Matzinger O; Haustermans K; Peiffert D; Glynne-Jones R; Winter KA; Konski AA; Ajani JA; Bosset JF; Hannoun-Levi JM; Puyraveau M; Chakravarthy AB; Meadows H; Northover J; Collette L; Christiaens M; Maingon P
Eur J Cancer; 2019 Nov; 121():130-143. PubMed ID: 31574418
[TBL] [Abstract][Full Text] [Related]
4. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
[TBL] [Abstract][Full Text] [Related]
5. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy.
Weber DC; Kurtz JM; Allal AS
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):675-80. PubMed ID: 11395235
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a 36 Gy elective node irradiation dose in anal cancer.
Lépinoy A; Lescut N; Puyraveau M; Caubet M; Boustani J; Lakkis Z; Fantoli M; Buffet-Miny J; Kim S; Bednarek C; Maingon P; Créhange G; Bosset JF
Radiother Oncol; 2015 Aug; 116(2):197-201. PubMed ID: 26277433
[TBL] [Abstract][Full Text] [Related]
7. [Brachytherapy for anal cancers].
Pommier P; Mirabel X; Hannoun-Lévi JM; Malet C; Gérard JP; Peiffert D
Cancer Radiother; 2013 Apr; 17(2):143-50. PubMed ID: 23582604
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
[TBL] [Abstract][Full Text] [Related]
9. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
Ferrigno R; Nakamura RA; Dos Santos Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV; Filho WJ; Lopes A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1136-42. PubMed ID: 15752894
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
[TBL] [Abstract][Full Text] [Related]
13. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
[TBL] [Abstract][Full Text] [Related]
14. Treatment of anal carcinoma in the elderly: feasibility and outcome of radical radiotherapy with or without concomitant chemotherapy.
Allal AS; Obradovic M; Laurencet F; Roth AD; Spada A; Marti MC; Kurtz JM
Cancer; 1999 Jan; 85(1):26-31. PubMed ID: 9921970
[TBL] [Abstract][Full Text] [Related]
15. Impact of advancing age on treatment and outcomes in anal cancer.
Foo M; Link E; Leong T; Chu J; Lee MT; Chander S; Tran PK; Tomaszewski JM; Michael M; Heriot A; Ngan SY
Acta Oncol; 2014 Jul; 53(7):909-16. PubMed ID: 24456502
[TBL] [Abstract][Full Text] [Related]
16. Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
Chen YW; Yen SH; Chen SY; Huang PI; Shiau CY; Liu YM; Lin JK; Wang LW
J Surg Oncol; 2007 Oct; 96(5):374-80. PubMed ID: 17492635
[TBL] [Abstract][Full Text] [Related]
17. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
18. Twenty-five-year experience with radical chemoradiation for anal cancer.
Tomaszewski JM; Link E; Leong T; Heriot A; Vazquez M; Chander S; Chu J; Foo M; Lee MT; Lynch CA; Mackay J; Michael M; Tran P; Ngan SY
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):552-8. PubMed ID: 22019078
[TBL] [Abstract][Full Text] [Related]
19. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Budach V; Stromberger C; Poettgen C; Baumann M; Budach W; Grabenbauer G; Marnitz S; Olze H; Wernecke KD; Ghadjar P
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):916-24. PubMed ID: 25670541
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).
Glynne-Jones R; Sebag-Montefiore D; Adams R; Gollins S; Harrison M; Meadows HM; Jitlal M;
Cancer; 2013 Feb; 119(4):748-55. PubMed ID: 23011911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
